A Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic

NCT ID: NCT05144685

Last Updated: 2025-06-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

356 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-07

Study Completion Date

2024-06-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to assess the effectiveness of a digital intervention in reducing suicide attempts.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This double blind, randomized controlled trial will evaluate effectiveness of two digital interventions among 391 participants. Study participation will start when participants sign consent. Participants and research assessors will be blinded to treatment assignment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Suicide, Attempted Suicidal Ideation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors
Participants and research assessors will be blinded to treatment assignment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental App + Treatment as Usual

This intervention will be for the treatment group

Group Type EXPERIMENTAL

OTX-202

Intervention Type DEVICE

Experimental Pscyhoeducation and Intervention App

Treatment as Usual

Intervention Type BEHAVIORAL

Treatment as usual may include appointments with psychiatrists and other mental health clinicians, suicide risk assessment, supportive listening, crisis resources, clinician assessment, and referral to outpatient treatment.

Other App + Treatment as Usual

This intervention will be for the control group

Group Type EXPERIMENTAL

OTX-000

Intervention Type DEVICE

Other Pscyhoeducation App

Treatment as Usual

Intervention Type BEHAVIORAL

Treatment as usual may include appointments with psychiatrists and other mental health clinicians, suicide risk assessment, supportive listening, crisis resources, clinician assessment, and referral to outpatient treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OTX-202

Experimental Pscyhoeducation and Intervention App

Intervention Type DEVICE

OTX-000

Other Pscyhoeducation App

Intervention Type DEVICE

Treatment as Usual

Treatment as usual may include appointments with psychiatrists and other mental health clinicians, suicide risk assessment, supportive listening, crisis resources, clinician assessment, and referral to outpatient treatment.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TAU

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ages ≥18 years old
2. Patients recently hospitalized.
3. Owns a smartphone.
4. Willing and able to complete enrollment procedures.
5. Able to understand the nature of the study.
6. Able and willing to provide at least two verifiable contacts.

Exclusion Criteria

1. Patients who have untreated psychosis or active psychosis
2. Patients who appear to be impaired by the use of alcohol or other substance(s)
3. Patients who sign, or have signed, an informed consent form to participate in any clinical research
4. Patients who upon clinical examination are cognitively impaired
5. Patients with a medical condition that may compromise, interfere, limit, effect or reduce the subject's ability to complete
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Mental Health (NIMH)

NIH

Sponsor Role collaborator

Oui Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UCDDenver / Denver Health

Denver, Colorado, United States

Site Status

Yale

New Haven, Connecticut, United States

Site Status

Common Spirit

Omaha, Nebraska, United States

Site Status

Northwell Health

Glen Oaks, New York, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

Harding Hospital

Columbus, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Bryan CJ, Simon P, Wilkinson ST, Allen MH, Perez J, Adler C, Moon K, Astorino L, Carpenter KM, Misquitta L, Brownlowe K, Khazem LR, Hay J, Starkey AG, Tartaglia J, Winston H, Simpson S, Dager AD, Feuerstein S. A Digital Therapeutic Intervention for Inpatients With Elevated Suicide Risk: A Randomized Clinical Trial. JAMA Netw Open. 2025 Aug 1;8(8):e2525809. doi: 10.1001/jamanetworkopen.2025.25809.

Reference Type DERIVED
PMID: 40779267 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2R42MH123357-02

Identifier Type: NIH

Identifier Source: secondary_id

View Link

2020-Oui-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.